Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Date:6/30/2008

rrently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel as a treatment for migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosis and epilepsy. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements, including whether any preclinical studies or clinical trials conducted in the future, will prove successful, and if successful, whether the results can be replicated. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact:

Paul Schneider

TorreyPines Therapeutics, Inc.

858-623-5665, x125

pschneider@torreypinestherapeutics.com

Media Contact:

David Schull

Russo Partners, LLC

212-845-4271

david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary Recall ... Junctional Tourniquet.  Photo - ... announced today that it has begun notifying customers ... issue with a clip used to secure the ... the SAM Junctional Tourniquet (SJT).  The company discovered ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... to Phase 3; Eligible for Accelerated Approval; ... Global Regulatory Plan Expected by Year End, CRANBURY, ... a biopharmaceutical company developing small molecule,orally-administered pharmacological chaperones for ... has successfully completed an End,of Phase 2 meeting for ...
... Rare Genetic Disorder in,Children--, PHILADELPHIA, July 31 ... levels of blood sugar in animals genetically,engineered to ... in humans, it could become an innovative medicine ... devastating genetic,disease in which insulin levels become dangerously ...
Cached Medicine Technology:Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 2Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 3Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 4Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
(Date:9/2/2014)... public support for marijuana legalization in the U.S. has ... than other substances, such as alcohol. In January, President ... marijuana is more dangerous than alcohol. Despite the recent ... as compared to alcohol use are not well understood. ... Outcomes Associated with Drug Use among US High School ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the ... Prosupps will be an exhibitor at the Las ... Rd, Las Vegas, NV 89109 Booth #374 Sept 19th ... to encourage healthy living through exercise, diet and supplementation. ... vision, and provide the tools for all Prosupps customers ...
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give ... a US-made toothbrush. For every toothbrush purchased, Smile Squared ... Squared was created by my wife and me after ... Cope, President of Smile Squared. “There, we saw children ... many of the same children didn't own a toothbrush. ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2
... MISSISSAUGA, ON, May 13 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. ... Drug Application (NDA),has been submitted to the U.S. ... extended-release formulation of tramadol. In May 2007,the Company ... to its,NDA for CIP-TRAMADOL ER., Cipher,s revised ...
... May 13 Lumenis Inc., a global,developer, ... radiofrequency,devices for surgical, aesthetic, and ophthalmic applications, ... Enucleation of the Prostate (HoLEP),preceptor program that ... interested in learning and performing HoLEP. The ...
... Project proceeds despite non-compliance with California Environmental ... Quality ... Center (PHCMC) today went ahead with the planned expansion of its,Holy ... has upheld charges that the approval process was significantly flawed.,The groundbreaking ...
... 12 /PRNewswire-FirstCall/ - Med-Emerg International Inc.,(OTCBB - MDER), ... three months ended March 31, 2008 were $5.5 ... in 2007 (all amounts are $US unless,otherwise stated). ... interest and taxes (EBITDA) improved to $179K,from a ...
... TSX:,WHT) World Heart Corporation ("WorldHeart" or the "Corporation") ... Bulletin today advising it,is reviewing the eligibility for ... of WorldHeart under sections 709 and 710(a) of ... Company,s financial condition and,operating results, more specifically whether ...
... Institute (KGI),today announced that the May 17, 2008, commencement ... Applied Life Sciences student, Eric,Tan, and the unveiling of ... and proud of Eric,s achievement in becoming the,first graduate ... KGI,s senior,vice president for academic affairs, dean of faculty ...
Cached Medicine News:Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 2Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 3Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2
... The ImmunoWELL VZV IgG ... for the qualitative detection of ... (VZV). Test results are used ... status or infection. Immune status ...
... Test is an enzyme immunoassay (EIA) test ... human thyroglobulin and human thyroid peroxidase (microsome) ... is used as an aid in the ... disorders are characterized by detection of anti-thyroid ...
... ImmunoDOT Autoimmunity Screening Panel 1 is ... screening and detection of autoantibodies against ... SS-A/SS-B, RNP/Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
... Antibody (IgG) Test is an ... quantitative detection of antibodies to ... is used as an aid ... thrombosis in individuals with systemic ...
Medicine Products: